Disclosed are compositions of matter, therapeutic protocols, and cellular reprogramming means to inhibit glioma or other brain neoplasia. In one embodiment the invention provides administration of amniotic fluid derived stem cells at concentrations of 1 million to 200 million administered in a manner to provide a differentiation stimulation, resulting in reduction of malignant potential. In other embodiments, an unexpected synergy of cancer inhibitory soluble factor production is disclosed by combined cultures between amniotic fluid stem cells and monocytes. In all embodiments cells may be autologous or allogeneic. The invention provides means of augmenting efficacy of immunotherapy, chemotherapy, and radiotherapy.